Increased IL-1β and Decreased SOD2 mRNA Expression in Cholesteatoma Compared with Postauricular Skin in Cholesteatomatous Otitis Media
Antioxidants · 08.11.2026 · 15 (11) · 1446
DOI: 10.3390/antiox15111446 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antioxidants, online erschienen am 08.11.2026. Verfasst von Jeon Gang Doo und 10 weiteren Autor:innen. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Education of the Republic of Korea and the National Research Foundation of Korea (NRF) grant, four ministries (Ministry of Health and Welfare, Ministry of Science and ICT, Ministry of Trade, Industry and Resources, and Korea Disease Control and Preventi….
Abstract (Originalsprache)
Background
Cholesteatomatous otitis media (CholeOM) is a non-cancerous growth characterized by severe clinical manifestations, a high risk of complications, and a high rate of recurrence after surgery, but understanding of its pathogenesis is incomplete. This study investigated the relationships of the expression levels of IL-1β (a pro-inflammatory cytokine), NOX4 (an NADPH oxidase), and three antioxidant genes (CAT, HO-1, and SOD2) with the pathogenesis and clinical features of CholeOM.
Methods
Clinical and audiological characteristics were evaluated in 60 patients undergoing surgery for CholeOM. The mRNA expression levels of five target genes (IL-1β, NOX4, CAT, HO-1, and SOD2) were determined by quantitative real-time PCR in successfully extracted unpaired surgical cholesteatoma (n = 23) and postauricular skin (n = 32) tissue specimens.
Results
Otorrhea was present in 58.3% of patients, bacterial cultures were positive in 16.7% of patients, and conductive hearing loss (63.3%) was more common than sensorineural hearing loss (35.0%) and normal hearing (1.7%). Comparison of gene expression in cholesteatoma and postauricular skin indicated the cholesteatoma had significantly greater expression of IL-1β (p = 0.024) and significantly less expression of SOD2 (p < 0.001), but there were no differences in the expression of NOX4, CAT, and HO-1 (all p > 0.05). The expression of these five genes in cholesteatoma was unrelated to sex, history of revision surgery, presence of otorrhea, or type of hearing loss (all p > 0.05).
Conclusions
Comparison of gene expression indicated cholesteatoma had significantly increased expression of IL-1β and decreased expression of SOD2 compared to postauricular skin. These changes highlight distinct inflammatory and oxidative stress profiles in cholesteatoma tissue, though causal links to the initial pathogenesis of CholeOM require further investigation using normal middle-ear mucosa controls.
Förderung
- Ministry of Education of the Republic of Korea and the National Research Foundation of Korea (NRF) grant
- four ministries (Ministry of Health and Welfare, Ministry of Science and ICT, Ministry of Trade, Industry and Resources, and Korea Disease Control and Preventi…
Zitieren
APA
Doo, J. G., Lee, J. M., Kim, J. M., Kim, H. O., Choi, M., Park, M., Kang, I. U., Singh, M. K., Kim, S. S., Park, D. C., & Yeo, S. G. (2026). Increased IL-1β and Decreased SOD2 mRNA Expression in Cholesteatoma Compared with Postauricular Skin in Cholesteatomatous Otitis Media. Antioxidants, 15(11), 1446. https://doi.org/10.3390/antiox15111446
Vancouver
Doo JG, Lee JM, Kim JM, Kim HO, Choi M, Park M, et al. Increased IL-1β and Decreased SOD2 mRNA Expression in Cholesteatoma Compared with Postauricular Skin in Cholesteatomatous Otitis Media. Antioxidants. 2026;15(11):1446. doi:10.3390/antiox15111446
BibTeX
@article{Doo2026,
author = {Doo, Jeon Gang and Lee, Jae Min and Kim, Jung Min and Kim, Hye Ok and Choi, Minji and Park, Minsuh and Kang, In Uk and Singh, Manish Kumar and Kim, Sung Soo and Park, Dong Choon and Yeo, Seung Geun},
title = {Increased IL-1β and Decreased SOD2 mRNA Expression in Cholesteatoma Compared with Postauricular Skin in Cholesteatomatous Otitis Media},
journal = {Antioxidants},
year = {2026},
volume = {15},
number = {11},
pages = {1446},
doi = {10.3390/antiox15111446}
}
EUVIMED